Ocular safety of infliximab in rabbit and cell culture models

Journal of Ocular Pharmacology and Therapeutics

Volumn 26, Issue 1, 2010, Pages 65-71

  Giansanti, Fabrizio ^a   Papucci, Laura ^a   Capaccioli, Sergio ^a   Bacherini, Daniela ^a   Vannozzi, Lorenzo ^a   Witort, Ewa ^a   Menchini, Ugo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; INFLIXIMAB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG SAFETY; ELECTRORETINOGRAM; HISTOLOGY; NONHUMAN; PIGMENT EPITHELIUM; RABBIT; RETINA GANGLION CELL; SINGLE DRUG DOSE; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CELL LINE; CELL PROLIFERATION; ELECTRORETINOGRAPHY; HUMANS; RABBITS; RETINA; RETINAL GANGLION CELLS; RETINAL PIGMENT EPITHELIUM; TOXICITY TESTS;

EID: 77649278043     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0035     Document Type: Article

References (26)

1. Bazzoni, F., and Beutler, B. The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334:1717-1725, 1996.
2. Ooi, K.G., Galatowicz, G., Calder, V.L., et al. Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype? Clin. Med. Res. 4:294-309, 2006.
3. Theodossiadis, P.G., Markomichelakis, N.N., and Sfi kakis, P.P. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina. 27:399-413, 2007.
4. Dick, A.D., Forrester, J.V., Liversidge, J., et al. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog. Retin. Eye Res. 23:617-637, 2004.
5. Joussen, A.M., Murata, T., Tsujikawa, A., et al. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am. J. Pathol. 158:147-152, 2001.
6. Joussen, A.M., Poulaki, V., Le, M.L., et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18:1450-1452, 2004.
7. Limb, G.A., Webster, L., Soomro, H., et al. Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin. Exp. Immunol. 118:213-218, 1999.
8. Limb, G.A., Hollifi eld, R.D., Webster, L., et al. Soluble TNF receptors in vitreoretinal proliferative disease. Invest. Ophthalmol. Vis. Sci. 42:1586-1591, 2001.
9. Doganay, S., Evereklioglu, C., Er, H., et al. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye. 16:163-170, 2002.
10. Sfi kakis, P.P., Markomichelakis, N., Theodossiadis, G.P., et al. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care. 28:445-447, 2005.
11. Shi, X., Semkova, I., Müther, P.S., et al. Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization. Exp. Eye Res. 83:1325-1334, 2006.
12. Markomichelakis, N.N., Theodossiadis, P.G., and Sfi kakis, P.P. Regression of neovascular age-related macular degeneration following infliximab therapy. Am. J. Ophthalmol. 139:537-540, 2005.
13. Nussenblatt, R. Treating intraocular inflammatory disease in the 21st century. Arch. Ophthalmol. 123:1000-1001, 2005.
14. Sfi kakis, P.P., Theodossiadis, P.G., Katsiari, C.G., et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet. 358:295-296, 2001.
15. Theodossiadis, P.G., Liarakos, V.S., Sfikakis, P.P., et al. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am. J. Ophthalmol. 147:825-30, 830.e1, 2009.
16. Meredith, T.A., Trabelsi, A., Miller, M.J., et al. Spontaneous sterilization in experimental Staphylococcus epidermidis endophthalmitis. Invest. Ophthalmol. Vis. Sci. 31:181-186, 1990.
17. Dunn, K.C., Aotaki-Keen, A.E., Putkey, F.R., et al. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp. Eye Res. 62:155-169, 1996.
18. Krishnamoorthy, R.R., Agarwal, P., Prasanna, G., et al. Characterization of a transformed rat retinal ganglion cell line. Brain Res. Mol. Brain Res. 86:1-12, 2001.
19. Maher, P., and Hanneken, A. The molecular basis of oxidative stress-induced cell death in an immortalized retinal ganglion cell line. Invest. Ophthalmol. Vis. Sci. 46:749-757, 2005.
20. Agar, A., Li, S., Agarwal, N., et al. Retinal ganglion cell line apoptosis induced by hydrostatic pressure. Brain Res. 1086:191-200, 2006.
21. Luzi, E., Papucci, L., Schiavone, N., et al. Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modifi ed, synthetic ribozyme. Cancer Gene Ther. 10:201-208, 2003.
22. Manzano, R.P., Peyman, G.A., Khan, P., et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 26:257-261, 2006.
23. Giansanti, F., Ramazzotti, M., Vannozzi, L., et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest. Ophthalmol. Vis. Sci. 49:1151-1156, 2008.
24. Theodossiadis, P.G., Liarakos, V.S., Sfikakis, P.P., et al. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch. Clin. Exp. Ophthalmol. 247:273-281, 2009.
25. Tempestini, A., Schiavone, N., Papucci, L., et al. The mechanisms of apoptosis in biology and medicine: a new focus for ophthalmology. Eur. J. Ophthalmol. 13(Suppl 3):S11-S18, 2003.
26. Zhang, Y., and Bhavnani, B.R. Glutamate-induced apoptosis in primary cortical neurons is inhibited by equine estrogens via down-regulation of caspase-3 and prevention of mitochondrial cytochrome C release. BMC Neurosci. 6:13, 2005.